Adaptin Bio (APTN) Research & Development (2024 - 2026)

Adaptin Bio (APTN) has 3 years of Research & Development data on file, last reported at $165577.0 in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 166.49% year-over-year to $165577.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 11.25% YoY), and the FY2025 full-year result was $1.8 million, down 2.76% from the prior year.
• Research & Development slipped to $165577.0 in Q1 2026, from $593035.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $778664.0 in Q3 2025 to a low of $62133.0 in Q1 2025.
• A 3-year average of $418259.3 and a median of $340334.0 in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development plunged 68.77% in 2025 and jumped 166.49% in 2026, its largest moves.
• Tracing APTN's Research & Development over 3 years: stood at $258058.0 in 2024, then soared by 129.81% to $593035.0 in 2025, then sank by 72.08% to $165577.0 in 2026.
• Business Quant data shows APTN's Research & Development at $165577.0 in Q1 2026, $593035.0 in Q4 2025, and $778664.0 in Q3 2025.